On the Couch with Jon Pilcher (Neuren): DAYBUE, Europe and What Comes Next
About this episode
Henry Jennings speaks with Jon Pilcher about Neuren Pharmaceuticals' recent challenges and future prospects.
In this episode of On the Couch, Henry Jennings speaks with Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX: NEU), on his fourth appearance on the podcast. They cover the European regulatory setback, strong US sales momentum, and what the phase three trial for Neuren's second drug candidate means for the company's outlook. — Marcus Today – Daily Market Insights Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios, education, and decision...
Topics covered
- European regulatory setback
- US sales momentum
- phase three trial
- Neuren Pharmaceuticals
- drug candidate
- market outlook
More episodes of On the Couch
Explore listener stats, chart rankings, contacts and more on the On the Couch podcast page.